MBT STAR®-Cepha IVD Assay – Rapid Cephalosporinase Detection

Recognize multi-drug resistant bacteria

To counteract the rise of multidrug-resistant bacteria, Bruker is dedicated to developing new solutions to keep pace. The rapid identification and determination of resistance is a crucial basis for clinicians and physicians to provide their patients as quickly as possible with the antibiotic that promises rapid, gentle and appropriate treatment.

The MBT STAR®-Cepha IVD Assay, Bruker's latest development, makes a valuable contribution to this critical topic as it detects resistances towards 3rd generation cephalosporins within just one hour after a positive blood culture alert.

Detection of ESBL and AmpC cephalosporinase activity

Together with the IVD MALDI Biotyper®, the MBT STAR®-Cepha IVD Kit enables detection of the characteristic enzymatic hydrolysis of the β-lactam ring of 3rd generation cephalosporin antibiotics. The level of hydrolysis is measured by acquisition of mass spectra in the typical mass range of the antibiotic. The assay allows detection of most actively expressed ESBL and AmpC β-lactamases in multidrug-resistant Gram-negative Enterobacterales:


  • for example, plasmidic TEM, SHV and CTX-M


  • chromosomal and plasmidic
  • inducible or overexpressed resistance genes, for example AmpC, FOX, LAT, DHA and CMY
Hydrolysis of an antibiotics ss lactam ring leads to mass shifts that can easily be detected by MALDI TOF mass spectrometry 500px
Hydrolysis of an antibiotics ß-lactam ring leads to mass shifts that can easily be detected by MALDI-TOF mass-spectrometry

Simple workflow - fast results

Starting from a positively flagged blood culture, processed by the rapid Sepsityper® workflow, or a (sub)culture plate, results are typically available within 60 minutes.

For this purpose, bacteria are incubated with a benchmark 3rd generation cephalosporin antibiotic, conveniently provided in a microtiter plate contained in the kit.

After an assay incubation period of 30 minutes, aliquots are transferred onto a MALDI target plate, covered with dedicated MBT STAR® Matrix, and analyzed at the level of the antibiotic, using the IVD MALDI Biotyper® mass spectrometer.

The presence of cephalosporinase activity results in specific mass shifts of the antibiotic, evaluated by the MBT STAR®-BL IVD Module for MBT Compass IVD. Acquired mass spectrometric data are processed and the ratio of hydrolyzed to non-hydrolyzed cephalosporin antibiotic is calculated automatically and instantly in the background by the MBT STAR®-BL IVD Module. The user receives a final report including assay results interpretation, facilitated by means of simple color coding indicating the status of enzyme activity.

STAR workflow
STAR® workflow

State-of-the-art patient care and infection control

With a lead time of one hour - from positive blood culture alert to outcome - the MBT STAR®-Cepha IVD Assay is ideal for screening and confirming findings to ensure effective patient care and infection control.

MBT STAR Cepha IVD kit